Caliper Life Sciences Licenses Monogram Biosciences' Microfluidics Patents
May 02 2007 - 5:00PM
PR Newswire (US)
- Additional Intellectual Property Portfolio to Expand and
Strengthen Caliper Driven(TM) Licensing Program - HOPKINTON, Mass.
and SOUTH SAN FRANCISCO, Calif., May 2 /PRNewswire-FirstCall/ --
Caliper Life Sciences, Inc. (NASDAQ:CALP) and Monogram Biosciences,
Inc. (NASDAQ:MGRM), today announced an agreement under which
Monogram has licensed most of its microfluidics patent portfolio to
Caliper on an exclusive basis. The intellectual property licensed
to Caliper originates from ACLARA BioSciences, which merged with
Monogram in December of 2004. Financial terms of the agreement were
not disclosed. Caliper, a pioneer in the development and
commercialization of microfluidics, continues to seek opportunities
to maximize the commercialization of this technology and more fully
exploit its advantages for drug discovery and diagnostic
applications. Through the agreement with Monogram, Caliper has
created the most comprehensive, unrivaled microfluidics patent
estate, further solidifying the company's Caliper Driven licensing
program. With the addition of the patents exclusively licensed from
Monogram, the Caliper patent estate available for licensing under
the Caliper Driven program now includes more than 335 United States
patents. "Microfluidics technology is gaining main-stream market
adoption. It is a next-generation experimentation platform offering
unprecedented data quality, workflow integration and scalability
for critical research and diagnostic applications," said Kevin
Hrusovsky, CEO of Caliper Life Sciences. "By incorporating
Monogram's microfluidic patent estate into our own, we are able to
expand the overall breadth and versatility of the applications that
we can now pursue -- either on our own or with partners through our
Caliper Driven program." "Caliper is the undisputed leader in
developing the power of microfluidics," said Michael Dunn, chief
business officer of Monogram Biosciences. "Given this leadership
position, we see many advantages to combining our microfluidics
intellectual property with Caliper's commercialization engine to
further exploit the power of this innovative technology."
Microfluidic technology represents a revolution in laboratory
experimentation, bringing the benefits of miniaturization,
integration and automation to many research-based industries.
Currently, 18 of the top 20 pharmaceutical companies, including
AstraZeneca, Novartis and Vertex, along with a growing number of
biotechnology and research institutions use Caliper's
microfluidic-based LabChip(R) systems. Caliper has also partnered
with companies such as Affymetrix, Agilent Technologies, Bio-Rad
Laboratories, Canon U.S. Life Sciences and Wako Pure Chemicals to
further develop and commercialize LabChip-based solutions. Under
the terms of the license agreement, Monogram retains the right to
practice the licensed microfluidics intellectual property for use
with its proprietary eTag(TM) technology. About Caliper Life
Sciences Caliper Life Sciences is a leading provider of drug
discovery and life sciences research solutions for the
pharmaceutical and biotechnology industries. With its acquisitions
of NovaScreen Biosciences and Xenogen Corporation, Caliper has
positioned itself to transform drug discovery and development
through a keen focus on clinically relevant experimentation.
Caliper's products and services, assembled from a leading portfolio
of microfluidics, liquid handling, and imaging technologies, span
in vitro and in vivo experimentation and address key issues on the
critical path of drug discovery and development. More information
about Caliper can be found at http://www.caliperls.com/. About
Monogram Biosciences, Inc. Monogram is advancing individualized
medicine by discovering, developing and marketing innovative
products to guide and improve treatment of serious infectious
diseases and cancer. The Company's products are designed to help
doctors optimize treatment regimens for their patients that lead to
better outcomes and reduced costs. The Company's technology is also
being used by numerous biopharmaceutical companies to develop new
and improved antiviral therapeutics and vaccines as well as
targeted cancer therapeutics. More information about the Company
and its technology can be found on its web site at
http://www.monogrambio.com/. The statements in this press release
regarding future events, including statements regarding Caliper's
and Monogram's plans to maximize the commercialization of
microfluidic technology through the combination of their
microfluidic patent estates and to more fully exploit the
advantages of microfluidic technology for drug discovery and
diagnostic applications, are "forward-looking statements" within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended. These statements are subject to risks and uncertainties
that could cause actual results to differ materially from those
contemplated by the forward-looking statement as a result of a
number of factors, including the risk that unexpected difficulties
may be encountered in developing new products based on microfluidic
technology or in gaining wide commercial adoption of any newly
developed products. Further information on risks faced by Caliper
with respect to its microfluidic technology are detailed under the
caption "Risks Related To Our Business" in Caliper's Annual Report
on Form 10-K for the year ended December 31, 2006. Further
information on risks faced by Monogram with respect to its
microfluidic intellectual property are detailed in the "Risk
Factors" section of Monogram's Annual Report on Form 10-K for the
year ended December 31, 2006. These filings are available on a web
site maintained by the Securities and Exchange Commission at
http://www.sec.gov/. Caliper and Monogram do not undertake any
obligation to update forward-looking or other statements in this
release. NOTE: LabChip is a registered trademark, and Caliper
Driven is a trademark, of Caliper Life Sciences, Inc. eTag is a
trademark of Monogram Biosciences, Inc. DATASOURCE: Caliper Life
Sciences, Inc. CONTACT: Stacey Holifield, or Melissa Bruno, both of
Schwartz Communications, +1-781-684-0770, for Caliper Life
Sciences; or Jeremiah Hall of Feinstein Keane, +1-415-677-2720, for
Monogram Biosciences Web site: http://www.monogrambio.com/ Web
site: http://www.caliperls.com/
Copyright
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Jul 2023 to Jul 2024